

PRESS RELEASE

Regeneus enters into US marketing trial agreement for novel canine cancer vaccine

Sydney, Australia – 30 June 2014

Regenerative medicine company, Regeneus (ASX: RGS) announced today that it has entered into an agreement with a leading US vet health care services group to conduct a marketing trial in the United States of the company's novel autologous canine therapeutic cancer vaccine, Kvac.

"We are delighted that we have now agreed the design and implementation of our initial US marketing trial for Kvac. The trial will provide important efficacy data in a single defined tumour type and increase awareness of the new cancer treatment with vets and dog owners in the United States," says Dr Duncan Thomson – Head of the Veterinary Business Unit for Regeneus.

This follows on from the company's announcement in November 2013 that the US Center for Veterinary Biologics gave the green light for the US commercialisation of Kvac and in April 2014, that Regeneus entered into an agreement with Hennessy Research to manufacture the vaccine for the US market.

Kvac uses the removal of a small amount of tumour or biopsy from the patient as source material to produce a truly personalised cancer treatment. The therapeutic vaccine stimulates the dog's immune system to see the cancer cells as foreign and helps prevent further growth of the tumour and the development of new tumours.

The cancer vaccine was developed at the Bill Walsh Translational Cancer Research Laboratory, which is part of the Kolling Institute of Medical Research at the Royal North Shore Hospital in Sydney. Positive safety and early efficacy data was published in February 2014 by *Cancer Immunology Research*, the peer-reviewed journal published by the American Association for Cancer Research.

The Morris Animal Foundation, a leading US non-profit animal research foundation, has found that cancer accounts for over half the deaths of dogs over 10 years of age, which is roughly the same rate as humans. It is estimated that more than 4 million dogs develop cancer in the US each year which equates to a newly diagnosed case every 8 seconds. It remains by far the largest health concern of dog owners.

ENDS

Contacts and further information:

Investors:

Sandra McIntosh
Company Secretary
Regeneus Ltd
T: +61 2 9499 8010
E: investors@regeneus.com.au or go to www.regeneus.com.au

Media:

Clare Serafini
Communications Manager

Regeneus Ltd

T: +61 2 9499 8010

Mobile: 0417 299 081

E: clare.serafini@regeneus.com.au or go to www.regeneus.com.au

About Regeneus:

Regeneus Ltd (ASX: RGS) is a Sydney-based ASX listed regenerative medicine company that develops and commercialises novel autologous (patient's cells) and allogeneic (donor cells) cell therapies for humans and animals. The company has a marketed autologous product using adipose (fat) derived stem cells to treat human osteoarthritis (OA), HiQCell, which has been used to treat over 1000 arthritic joints. The company plans to commence a clinical trial of allogeneic adipose stem cells to treat human OA in H12015.

Regeneus' lead product for the animal health market is CryoShot, a clinical stage allogeneic adipose stem cell product for the treatment of canine and equine OA. CryoShot is scheduled for a US registration trial in H12015. Regeneus also has a clinical stage autologous therapeutic vaccine for the treatment of canine cancer, Kvax, which will commence marketing trials in the US and Australia in H2 2014. The company holds an option over the rights for human applications of the cancer vaccine.